- Home
- NPKI vs AVTX Comparison
NPKI vs AVTX Comparison
Compare NPKI & AVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NPKI | AVTX |
|---|---|---|
| Founded | 1932 | 2011 |
| Country | United States | United States |
| Employees | 510 | 33 |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 982.5M |
| IPO Year | N/A | 2015 |
Fundamental Metrics
Financial Performance| Metric | NPKI | AVTX |
|---|---|---|
| Price | $13.47 | $18.46 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 8 |
| Target Price | $14.17 | ★ $40.57 |
| AVG Volume (30 Days) | 820.2K | ★ 835.6K |
| Earning Date | 04-30-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 72.07 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $27,813,137.00 |
| Revenue This Year | $16.39 | N/A |
| Revenue Next Year | $11.70 | N/A |
| P/E Ratio | $38.65 | ★ N/A |
| Revenue Growth | N/A | ★ 2312.27 |
| 52 Week Low | $9.26 | $8.29 |
| 52 Week High | $16.50 | $24.27 |
Technical Indicators
Market Signals| Indicator | NPKI | AVTX |
|---|---|---|
| Relative Strength Index (RSI) | 45.61 | 52.08 |
| Support Level | $13.34 | $17.32 |
| Resistance Level | $15.10 | $19.21 |
| Average True Range (ATR) | 0.65 | 1.19 |
| MACD | 0.00 | -0.12 |
| Stochastic Oscillator | 54.21 | 46.75 |
Price Performance
Historical ComparisonAbout NPKI NPK International Inc.
NPK International Inc is a temporary worksite access solutions company that manufactures, sells, and rents recyclable composite matting products, along with a full suite of services, including planning, logistics, and site restoration. The company generates majority of revenue from the rental of recyclable composite matting systems, along with related site construction and services to customers in various markets including power transmission, oil and natural gas exploration and production, pipeline, renewable energy, petrochemical, construction and other industries within the United States and United Kingdom. It generates maximum revenue from United States.
About AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical stage biotechnology company fully dedicated to developing IL-1B-based treatments for immune-mediated inflammatory diseases. The company's asset is Abdakibart (AVTX-009) an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalos pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein), AVTX-006 and AVTX-913.